MARK FESEN MD NPI 1639149545

NPI Details

Mark Fesen, MD is a medical oncology internal medicine in Great Bend, KS with 39 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Mark Fesen, MD NPI is 1639149545. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: RUTGERS NEW JERSEY MEDICAL SCHOOL
Graduation Year:1987

The provider's business location address is:

204 CLEVELAND ST
GREAT BEND, KS
ZIP 67530-563
Phone: (620) 792-5511
Fax: (620) 792-5977

The NPI 1639149545 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg (HCPCS:Q5112)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Telehealth originating site facility fee (HCPCS:Q3014)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Collection of blood sample from central venous tube (HCPCS:36592)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)

The enumeration date for this NPI number is 1/24/2006 and was last updated on 10/10/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: